mRNA 3'UTR demonstrated that the ARE cluster between the third and fifth AREs was responsible for TTP-mediated destabilization of IL-23 mRNA. A RNA electrophoretic mobility shift assay confirmed that TTP binds to this ARE cluster. Taken together, these results demonstrate that TTP acts as a negative regulator of IL-23 gene expression in mouse colon cancer cells and suggest its potential application as a novel therapeutic target to control IL-23-mediated tumor promotion.
INTRODUCTION
IL-23 is an important pro-inflammatory heterodimeric cytokine formed by linkage of p40 and p19 subunits that acts as a crucial regulator to drive a pathway that leads to the generation of IL-17-producing CD4 T cells (Aggarwal et al., 2003; Cua et al., 2003; Harrington et al., 2005; Langrish et al., 2004) . The induction of IL-23-mediated processes leads to recruitment of a range of inflammatory cells in addition to T helper 17 cells, and has been shown to be crucial to the pathogenesis of a number of immune-mediated inflammatory diseases (Langrish et al., 2005) . In a recent study, IL-23 emerged as a new player in the promotion of tumor growth and development through suppression of tumor infiltration of CD8+ T cells and promotion of tumor angiogenesis and metastases (Langowski et al., 2006; Teng et al., 2010) . Moreover, anti-IL-23 monoclonal antibody acts synergistically with targeted therapies or IL-2 to suppress tumor growth and metastases (Teng et al., 2011) , supporting the tumor-promoting activity of IL-23.
Many inflammatory cytokine and chemokine mRNAs are known to be unstable (Anderson, 2008) . Expression of these mRNAs is modulated by post-transcriptional control, which is strongly dependent on AU-rich element (ARE)-mediated mechanisms (Stoecklin and Anderson, 2006) . The AREs may destabilize inflammatory signaling mRNAs through specific binding of proteins that promote mRNA degradation (Caput et al., 1986; Shyu and Wilkinson 2000) . Tristetraprolin (TTP) is a well-characterized ARE-binding protein that is involved in posttranscriptional regulation of inflammatory cytokines, proto-oncogenes, and growth regulatory genes (Cha et al., 2011; Lee et al., 2010a; 2011; 2012; 2013) . TTP-knockout mice develop severe inflammatory arthritis and autoimmune dysfunction, indicating a role of TTP in limiting the inflammatory response (Taylor et al., 1996) .
Macrophages and DCs are known to be the predominant producers of IL-23 (Hunter, 2005) . The 3'UTR of IL-23 p19 mRNA contains multiple AREs and IL-23 p19 expression in macrophages is suppressed by TTP-mediated degradation of p19 mRNA (Qian et al., 2011) . Recently, it has been reported that IL-23 is highly expressed in many tumors, including breast, prostate, liver, and skin cancers and head and neck squamous cell carcinoma (HNSCC), and that levels of IL-23 correlate with tumor progression (Kesselring et al., 2010; Langowski et al., 2006; Martin-Orozco et al., 2009 ). However, there are no convincing studies demonstrating the molecular basis for the regulation of IL-23 in cancer cells.
In the present study, we provide evidence that TTP inhibits IL-23 expression by enhancing the decay of IL-23 p19 mRNA in cancer cells. IL-23 transcript was detected in CT26 colon cancer cells. Overexpression of TTP decreased IL-23 expression level whereas inhibition of TTP by siRNA increased it. IL-23 p19 mRNA contains five AREs within the 3'UTR, and the direct
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http://molcells.org Established in 1990 http://molcells.org binding of TTP to these AREs enhances decay of the mRNA. These results support a procarcinogenic role for IL-23 and suggest that TTP-mediated inhibition of IL-23 expression in cancer cells might provide a novel therapeutic strategy for the suppression of tumor-promoting inflammation.
MATERIALS AND METHODS

Cells
The CT26 and 293 EBNA cell lines were purchased from the American Type Culture Collection (USA) and maintained in RPMI 1640 media supplemented with 10% FBS (HyClone) at 37°C in a humidified atmosphere of 5% CO 2 .
Plasmids and siRNAs
The pcDNA6/V5-TTP construct has been described previously (Lee et al., 2010b) . Mouse IL-23 p19 3′UTR was PCR amplified from cDNA of CT26 cells using Taq polymerase (SunGenetics, Korea) and the primers CCGCTCGAGGAGCTCTGGGGA GCCCACACT and ATAAGAATGCGGCCGCGGGCGAAAAT GGTTACGATGTG (underlined letters indicate restriction sites). PCR products were inserted into the XhoI/NotI sites of a psi-CHECK2 Renilla/firefly dual-luciferase expression vector (Promega, USA) to generate the construct psiCHECK2/IL-23 3′UTR Full. The psiCHECK2/IL-23 3′UTR Full construct was used as a template to synthesize the deletion mutant construct psiCHECK2/IL-23 Frag-ΔARE. PCR primers used for mutant constructs were TAAGGGCTTTAAGTTATATGCCCTGAGAT AACT and AGTTATCTCAGGGCATATAACTTAAAGCCCTTA.
An oligonucleotide containing the five AUUUA motifs (ARE-1-5) of the IL-23 p19 mRNA 3′UTR was synthesized at Integrated DNA Technologies (USA) ( Table 1) . Mutant oligonucleotides in which single (ARE-M-1, ARE-M-2, ARE-M-3, ARE-M-4, or ARE-M-5) or all five AUUUA pentamers (ARE-M all) were sub-stituted with AGCA were also synthesized. The oligonucleotides were ligated into the XhoI/NotI site of the psiCHECK2 vector.
Small interfering RNAs (siRNAs) against mouse TTP (TTPsiRNA; sc-36760) and control siRNA (scRNA; sc-37007) were purchased from Santa Cruz Biotechnology (USA).
Transfections and luciferase assay
Cells (5 × 10 6 ) were electroporated with various plasmid constructs and siRNAs at 1,400 V and 30 ms using the Neon™ Transfection System (Invitrogen, USA) according to the manufacturer's instructions.
Lysates of transfected cells were mixed with luciferase assay reagent (Promega, USA) and the chemiluminescent signal was measured in a Wallac Victor 1420 Multilabel Counter (EG&G Wallac, Finland). Renilla luciferase activity of psiCHECK2/ IL-23 3′UTR Full was normalized to firefly luciferase for each sample.
Electrophoretic mobility shift assay (EMSA)
The biotinylated RNA probes for wild-type ARE (Oligo-ARE-3/4, 5′-CCUGUAUUUAUUUGAGCUAUUUAAGGAUCUAUUUAUG UUUAAGUAUUUAGAAAA-3′) and mutant ARE (Oligo-AREm3/4, 5′-CCUGUAGCAUUUGAGCUAGCAAGGAUCUAGCAU GUUUAAGUAGCAGAAAA-3′) were synthesized by Samchully Pharm. Co., LTD (Korea). A mutant RNA probe in which the AUUUA pentamers were all substituted with AGCA was used as a negative control. Cytoplasmic extracts were prepared from CT26 cells using NE-PER ® Nuclear and Cytoplasmic extraction Reagent (Thermo Pierce Biotechnology Scientific, USA). RNA EMSA was performed using the Lightshift ® Chemoluminescent EMSA Kit (Thermo Pierce Biotechnology Scientific) according to the manufacturer's instructions. Briefly, 20 fmol of biotinylated RNA was combined with 4 μg of cytoplasmic cellular protein in a binding buffer. For the supershift EMSA, anti-TTP antibody (ab36558, Abcam, USA) or control antibody (I-5381, Sigma) was added to the reaction mixture. After the addition of antibodies, reaction mixtures were incubated overnight on ice. The reaction products were resolved on 5% nondenaturing polyacrylamide gels in 0.5× Tris borate/EDTA buffer. Gels were transferred to nylon membrane (Hybond™-N + ) in 0.5× Tris borate/EDTA at 100 V and 4°C for 1 h. The RNAs were crosslinked to the membrane and detected using streptavidinhorseradish peroxidase binding and chemiluminescence.
SDS-PAGE analysis and immunoblotting
Proteins were resolved by SDS-PAGE, transferred to Hybond-P membranes (GE Healthcare Bio-Sciences Corp., USA), and probed with the appropriate dilution of anti-TTP antibody (ab36558, Abcam) and anti-V5 antibody GenWay) . Immunoreactivity was detected using the ECL detection system (GE Healthcare Bio-Sciences Corp.). Films were exposed at multiple time points to ensure that images were not saturated.
Quantitative real-time PCR
For kinetic analysis of mRNA expression, we used actinomycin D to inhibit transcription and assessed IL-23 p19 mRNA expression by quantitative real-time PCR (qRT-PCR). qRT-PCR was performed by monitoring the increase in fluorescence of the SYBR Green dye (QIAGEN, Germany) in real-time using ABI Prism 7900 HT. Specificity of each primer pair was confirmed by melting curve analysis and agarose gel electrophoresis. PCR primer pairs were as follows: qIL-23: ACTACAACCG ATCCACCTCAC and ACTTTGCCTCCCAGATCACAG; qGAPDH: ATCTTCAAGCCATCCTGTGTGC and TGCGCTTGTCACAT TTTTCTTG.
Statistics
For statistical comparisons, p values were determined using Student's t-test.
RESULTS
TTP regulates the expression level of IL-23
Chronic inflammation is thought to be the leading cause of many human cancers including colon cancer (Terzic et al., 2010) . The proinflammatory cytokine IL-23 has emerged as a new player in the promotion of tumor growth and development. It was recently reported that IL-23 expression is highly expressed in many tumors and that the level of IL-23 correlates with tumor progression. Here, we investigated whether TTP regulates the expression of IL-23 in CT26 colon cancer cells. To determine the effect of TTP on IL-23 expression, the TTP expression vector pcDNA6/V5-TTP or pcDNA6/V6 as a vector control was transfected into CT26 cells. Overexpression of TTP was confirmed by RT-PCR and Western blot analyses. The expression of IL-23 was significantly reduced in pcDNA6/V5-TTP-transfected cells compared with cells transfected with empty vector (Figs. 1A and 1B) .
Next, we determined whether specific inhibition of TTP by siRNA affected IL-23 expression in CT26 cells. Down-regulation of TTP by treatment with siRNA-TTP significantly increased the expression level of IL-23 (Figs. 1C and 1D) . However, treatment with a non-specific siRNA (scRNA) did not decrease the expression level of endogenous TTP or induce a change in
